Measuring lipoprotein(a) for cardiovascular disease prevention - in whom and when?

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Purpose of review
The aim of this study is to summarize major cardiovascular guideline recommendations on lipoprotein(a) and highlighting recent findings that emphasize how measuring lipoprotein(a) once in all adults is meaningful regardless of age, sex, comorbidities, or ethnicity.

Recent findings
Many international guidelines now recommend once in a lifetime measurement of lipoprotein(a) in all adult individuals to facilitate accurate risk prediction. Lipoprotein(a)-lowering therapy to reduce cardiovascular disease is on the horizon, with results from the first phase 3 trial expected in 2025.

Elevated lipoprotein(a) is an independent causal risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis and measuring lipoprotein(a) once in all individuals regardless of age, sex, comorbidities, or ethnicity is meaningful to aid in risk stratification.
TidsskriftCurrent Opinion in Cardiology
Udgave nummer1
Sider (fra-til)39-48
Antal sider10
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
This work was founded by the Department of Clinical Biochemistry, Copenhagen University Hospital - Herlev and Gentofte, Gangstedfonden, and was supported by a research grant from the Danish Cardiovascular Academy (Grant number 2022007-HF), which is funded by the Novo Nordisk Foundation, grant number NNF20SA0067242 and The Danish Heart Foundation.

Publisher Copyright:
© 2023 Wolters Kluwer Health, Inc. All rights reserved.

ID: 377939811